Deals Of The Week: GlaxoSmithKline/BARDA, Evotec/Roche, F-Star/Merck Serono
Executive Summary
Each week, “The Pink Sheet” presents commentary on some of the week’s most interesting business deals, contributed by the editors of the IN VIVO blog. Visit the blog at http://invivoblog.blogspot.com.
You may also be interested in...
BARDA Signs Biodefense Contracts With GSK And Soligenix
Under a pair of agreements announced Sept. 19, the HHS unit will stockpile 60,000 doses of GSK’s inhalation anthrax treatment and will fund development of a treatment for GI acute radiation syndrome by New Jersey biotech Soligenix.
BARDA To Fund Pediatric Development Of Cempra’s Solithromycin
Antibiotic-focused biotech can earn $58 million over five years under the government contract, which provides for testing of the novel macrolide in pediatric indications and for protection against bioterror-threat pathogens.
With Muted Expectations For Provenge, Dendreon Restructures, Cuts Staff
A quarter of its employees, including the COO and many in manufacturing and administrative positions, will be dismissed.